Enhertu vs. Kadcyla

Attribute	Enhertu	Kadcyla
Manufacturer	AstraZeneca and Daiichi Sankyo	Genentech
Generic Name	Trastuzumab deruxtecan	Ado-trastuzumab emtansine
Indication	Treatment of HER2-positive breast cancer	Treatment of HER2-positive breast cancer
Administration	IV infusion	IV infusion
Mechanism of Action	Antibody-drug conjugate	Antibody-drug conjugate

Introduction

Enhertu and Kadcyla are two medications that are commonly used in the treatment of certain types of cancer. Both drugs have shown promising results in clinical trials and have been approved by regulatory agencies for specific indications. In this article, we will compare the attributes of Enhertu and Kadcyla, including their mechanisms of action, side effects, efficacy, and cost.

Mechanism of Action

Enhertu, also known as trastuzumab deruxtecan, is an antibody-drug conjugate that targets HER2-positive cancer cells. It consists of an antibody that specifically binds to HER2 receptors on cancer cells, delivering a potent chemotherapy drug directly to the tumor cells. This targeted approach helps to minimize damage to healthy cells and reduce side effects.

Kadcyla, on the other hand, is a combination of trastuzumab, an antibody that targets HER2 receptors, and emtansine, a chemotherapy drug. Trastuzumab binds to HER2 receptors on cancer cells, while emtansine disrupts the cancer cell's ability to divide and grow. This dual mechanism of action makes Kadcyla an effective treatment for HER2-positive breast cancer.

Side Effects

Both Enhertu and Kadcyla can cause side effects, although the specific side effects may vary between the two drugs. Common side effects of Enhertu include nausea, fatigue, hair loss, and decreased appetite. In some cases, Enhertu can also cause more serious side effects such as interstitial lung disease and heart problems.

Kadcyla is also associated with side effects such as nausea, fatigue, and hair loss. In addition, Kadcyla can cause liver problems, low platelet counts, and an increased risk of bleeding. Patients taking Kadcyla may also experience infusion reactions, which can range from mild to severe.

Efficacy

Both Enhertu and Kadcyla have shown promising results in clinical trials, with significant improvements in progression-free survival and overall survival in patients with HER2-positive breast cancer. Enhertu has been shown to be effective in patients who have previously received treatment with other HER2-targeted therapies, while Kadcyla is often used as a second-line treatment after other therapies have failed.

Overall, the efficacy of Enhertu and Kadcyla is comparable, with both drugs demonstrating significant benefits in terms of tumor response and survival outcomes. The choice between Enhertu and Kadcyla may depend on factors such as the patient's treatment history, disease stage, and individual preferences.

Cost

One important factor to consider when comparing Enhertu and Kadcyla is the cost of treatment. Both drugs are expensive, with prices ranging from tens of thousands to hundreds of thousands of dollars per year. The cost of treatment with Enhertu or Kadcyla may be covered by insurance, but patients may still be responsible for significant out-of-pocket expenses.

Patients and healthcare providers should consider the cost of treatment when deciding between Enhertu and Kadcyla, as well as the potential benefits and risks of each drug. Some patients may be eligible for financial assistance programs or other forms of support to help offset the cost of treatment with Enhertu or Kadcyla.